title: Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.
abstract: OBJECTIVE
  To study the pharmacokinetics of SK&F 107647, a novel hematoregulatory agent, in rats, dogs, and patients with non-lymphoid solid tumor malignancy.
  
  
  METHODS
  Sprague Dawley rats and beagle dogs (n = 6 each; 3 M, 3 F) were given 25 mg/kg of SK&F 107467 as an iv bolus injection, and patients (n = 6; 4 M, 2 F) received 100 mg/kg as a 2 hour iv infusion. Plasma samples were assayed for drug using either HPLC (rat and dog) or RIA (human).
  
  
  RESULTS
  In each species the plasma clearance (CL) of SK&F 107647 was low in relation to hepatic blood flow, and the volume of distribution (Vd ss) was reflective of distribution to extracellular body water. The plasma CL in humans was near that of average glomerular filtration rate. Using allometric equations for interspecies scaling (Y = a.W(b)), body-weight normalized human pharmacokinetic data were reasonably predicted using either the body weight normalized rat or the dog data. The allometric exponents (b) for CL, Vd(ss), and T(1/2) of SK&F 107647 were 0.63, 0.94, and 0.29, respectively.
  
  
  CONCLUSIONS
  Use of a limited pool of available animal data allowed for reasonable predictions of human pharmacokinetics of SK&F 107647.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Department of Drug Metabolism, King of Prussia, Pennsylvania, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Brocks
authors.forename: M I
authors.initials: MI
authors.lastname: Freed
authors.forename: D E
authors.initials: DE
authors.lastname: Martin
authors.forename: T S
authors.initials: TS
authors.lastname: Sellers
authors.forename: N
authors.initials: N
authors.lastname: Mehdi
authors.forename: D R
authors.initials: DR
authors.lastname: Citerone
authors.forename: V
authors.initials: V
authors.lastname: Boppana
authors.forename: B
authors.initials: B
authors.lastname: Levitt
authors.forename: B E
authors.initials: BE
authors.lastname: Davies
authors.forename: J
authors.initials: J
authors.lastname: Nemunaitis
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
mesh_terms: D000276:Adjuvants, Immunologic / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000368:Aged; D000818:Animals; D004285:Dogs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009842:Oligopeptides / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity
chemical_list: D000276:Adjuvants, Immunologic; D009842:Oligopeptides; C086049:SK&F 107647